References
- Ravnborg L., Baastrup N., Svejgaard E. Onychomycosis in HIV‐infected patients. Acta Derm Venereol 1998; 78: 151–2
- Gupta A. K., Joseph W. S. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J Am Podiatr Med Assoc 2000; 90: 495–501
- Pittrof F., Gerhards J., Erni W., Klecak G. Loceryl nail lacquer – realization of a new galenical approach to onychomycosis therapy. Clin Exp Dermatol 1992; 17((Suppl 1))26–8
- Baran R. Ciclopirox nail lacquer: the first prescription topical therapy for onychomycosis – Introduction. J Am Acad Dermatol 2000; 43((4 Pt 2))S55–S56
- Marty J‐P. L. Amorolfine nail lacquer: a novel formulation. J Eur Acad Dermatol Venereol 1995; 4((Suppl 1))S17–S21
- Marty J‐P., Baran R. Transungual drug delivery systems: what's new and relevant. Textbook of cosmetic dermatology, 2nd edn, R Baran, H. I Maibach. Martin Dunitz, London 1998; 95–7, In
- Tulli A., Ruffilli M. P., De Simone C. The treatment of onychomycosis with a new form of tioconazole. Chemioterapia 1988; 7: 160–3
- Roberts D. T., Hay R. J., Doherty V. R., Richardson M. D., Clayton Y. M. Topical treatment of onychomycosis using bifonazole 1% urea/40% paste. Ann N Y Acad Sci 1988; 544: 586–7
- Hay R. J., Roberts D. T., Doherty V. R., Richardson M. D., Midgley G. The topical treatment of onychomycosis using a new combined urea/imidazole preparation. Clin Exp Dermatol 1988; 13: 164–7
- Lecha M., Alsina M., Torres‐Rodriguez J. M., de Erenchun F. R., Mirada A., Rossi A. B. An open‐label, multicenter study of the combination of amorolfine nail lacquer and oral itraconazole compared with oral itraconazole alone in the treatment of severe toenail onychomycosis. Curr Ther Res 2002; 63: 366–79
- Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost‐effective treatment for onychomycosis. Br J Dermatol 2001; 145((Suppl 60))15–19
- Gupta A. K. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000; 43((4 Suppl))S81–S95
- Reinel D., Clarke C. Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once‐weekly versus twice‐weekly. Clin Exp Dermatol 1992; 17((Suppl 1))44–9
- Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992; 17((Suppl 1))41–3
- Vidal. 2001, OVP‐Editions du vidal
- MIMS. Haymarket Medical Publications, July, London 2003
- List Rote. Guide to drugs marketed in Germany (including EU‐approved drugs & particular devices). 2003, Editio Cantor Verlag
- Pianetasalute. 2003
- Hay R. J., Mackie R. M., Clayton Y. M. Tioconazole nail solution – an open study of its efficacy in onychomycosis. Clin Exp Dermatol 1985; 10: 111–15
- Roberts D. T. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992; 126((Suppl 39))23–7
- Roberts D. T. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141((Suppl 56))1–4
- IMS; data. 2003
- Gupta A. K., Jain H. C., Lynde C. W., Macdonald P., Cooper E. A., Summerbell R. C. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000; 43((2 Pt 1))244–8
- Sais G., Jucgla A., Peyri J. Prevalence of dermatophyte onychomycosis in Spain: a cross‐sectional study. Br J Dermatol 1995; 132: 758–61